SecBot SecBot

ABSI

Absci Corp
Nasdaq· Services-Commercial Physical & Biological Research· CIK 0001672688 Biotech & Drug Discovery
$9.18 −0.19 (−2.03%)
Oct 23 4:00 PM ET · prev $9.37
Market cap
$1.6B
Small cap
Consensus
Buy
88% Buy or better · 17 analysts
Median target
🔒 Subscribers only
1 year
+115.0%
from $4.27 · Oct 24
30 days
−11.3%
from $10.35
52-week range
$2.30–11.62
−21% from high · low Mar 12
Avg volume 20D
3.90M
shares / day
Short interest
37.44M
≈21.8% of shares · +0.5%
Days to cover
7.5
at average volume
Insider net
+$652.0K
3 buyers · 2 sellers · since Jan 28
New fund stakes
3
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BULLISH 1 report · 90 days
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score ·Next Earnings date, Nov 12, 2026
Strongest BULLISH A strong institutional cluster emerged in Absci Corp during 2026-Q2, with 10 funds all accumulating…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $784.4K at an average $3.48. 2 insiders sold $132.3K. Price is 164% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 31 added (3 new), 16 trimmed or exited. Largest new: Vanguard Capital Management $71.0M, Adage Capital Partners Gp, L.L.C $66.1M.

  • AnalystsBULLISH

    15 of 17 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +0.5% to 37.44M shares. 7.5 days to cover, ≈21.8% of shares.

  • TrendDOWNTREND

    2% below its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$155.7M
in new stakes
FundMoveSharesValue
AMERIPRISE FINANCIAL INCDOUBLED6,991,763$81.0M
VANGUARD CAPITAL MANAGEMENT LLCNEW6,122,677$71.0M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW5,704,820$66.1M
D. E. Shaw & Co., Inc.DOUBLED5,239,754$60.7M
GOLDMAN SACHS GROUP INCDOUBLED1,732,324$20.1M
Nuveen, LLCDOUBLED1,723,979$20.0M
VOLORIDGE INVESTMENT MANAGEMENT, LLCNEW1,602,916$18.6M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED1,489,993$17.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 88% rate it Buy or better
Strong Buy4Buy11Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 16, 2026Keybanc
MAINTAIN
MAINTAINOverweight
Oct 12, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Oct 12, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 23, 2026Needham
REITERATE
REITERATEBuy
Sep 9, 2026LifeSci Capital
INITIATE
INITIATEOutperform
Sep 8, 2026BTIG
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$784.4K
bought · 3 insiders
$132.3K
sold · 2 insiders
+163.9%
vs their $3.48 cost
DateInsiderTypeValue
Oct 12, 2026
Jonasson Zachariah
CFO / CBO
TAX W/H$3.9K
Oct 12, 2026
Bedrick Todd
SVP, CAO
TAX W/H$226.8K
Oct 12, 2026
McClain Sean
Chief Executive Officer
TAX W/H$236.7K
Aug 31, 2026
Jonasson Zachariah
CFO / CBO
TAX W/H$72.5K
Aug 3, 2026
Somaratne Ransi Mudalinayake
CMO, Head of R&D
AWARD383,000 sh
Jun 30, 2026
Szela Mary T
Director
BUY$148.9K
Jun 24, 2026
McClain Sean
Chief Executive Officer
TAX W/H$603.5K
Jun 4, 2026
Rabinovitsj Daniel A
Director
AWARD10,100 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
37,442,385
shares short
+0.5%
vs prior settlement
7.5
days to cover
≈21.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 12, 2026 Insider
Jonasson Zachariah surrendered for taxes 387 shares
CFO / CBO @ $10.16 ($3.9K)
Oct 12, 2026 Insider
Bedrick Todd surrendered for taxes 22,325 shares
SVP, CAO @ $10.16 ($226.8K)
Oct 12, 2026 Insider
McClain Sean surrendered for taxes 23,293 shares
Chief Executive Officer @ $10.16 ($236.7K)
Aug 11, 2026 SEC
A strong institutional cluster emerged in Absci Corp during 2026-Q2, with 10 funds all accumulating positions totaling…
INST-CLUSTER — Impact 5/10
Aug 11, 2026 Earnings calendar
ABSI Q2 2026 Earnings Scheduled — 2026-08-11
Jul 7, 2026 SEC
Director Mary T. Szela purchased $149K of Absci Corp (ABSI) shares at $11.54 on June 30, 2026. The purchase is trivial…
INSIDER-BUY — Impact 2/10
Jun 30, 2026 Inst.
AMERIPRISE FINANCIAL INC — DOUBLED
6,991,763 shares ($81.0M)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — NEW
6,122,677 shares ($71.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Aug 11, 2026
Earnings date
ABSI Q2 2026 Earnings Scheduled — 2026-08-11
Jun 24, 2026
Activist
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci
Jun 24, 2026
FDA
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts
May 7, 2026
Short interest
FTD: ABSI — 148,715 shares ($0.9M) failed to deliver
Settlement: 20260507, Price: $5.95, FTD Value: $884,854.25, ABSCI CORP
May 7, 2026
Earnings date
ABSI Q1 2026 Earnings Scheduled — 2026-05-07

SecBot reports

7 filings · 3 press releases · 2 bullish · 0 bearish · 2 mixed · 3 neutral
All ABSI filing & press-release reports (10)